Following a public comment period, the Federal Trade Commission has approved a final order settling charges that the $8 billion merger between Endo International plc and Par Pharmaceuticals, Inc. would likely be anticompetitive.
Under the order, first announced in September 2015, the companies are required to sell Endo’s U.S. rights and assets for generic glycopyrrolate tablets, which are used with other drugs to treat certain types of ulcers, and generic methimazole tablets, which are used to treat the body’s production of excess thyroid hormone to Rising Pharmaceuticals.
The Commission vote approving the final order was 4-0. (FTC File No. 151 0137; the staff contact is Stephanie C. Bovee, Bureau of Competition, 202-326-2083)
The FTC’s Bureau of Competition works with the Bureau of Economics to investigate alleged anticompetitive business practices and, when appropriate, recommends that the Commission take law enforcement action. To inform the Bureau about particular business practices, call 202-326-3300, send an e-mail to email@example.com, or write to the Office of Policy and Coordination, Bureau of Competition, Federal Trade Commission, 600 Pennsylvania Ave., Room CC-5422, Washington, DC 20580. To learn more about the Bureau of Competition, read Competition Counts. Like the FTC on Facebook, follow us on Twitter, and subscribe to press releases for the latest FTC news and resources.
Office of Public Affairs